Serono to pay over $700 million to settle federal charges

Share this article:
Swiss drug maker Serono will pay more than $700 million to settle federal charges that it illegally marketed its AIDS drug Serostim by developing a fraudulent medical test to increase demand for the drug and sent doctors on all-expenses paid vacations to France in exchange for writing prescriptions.
The settlement marks the third largest healthcare fraud recovery in the history of the U.S. Justice Department and is the largest settlement involving losses to the federal- and state-funded Medicaid program.
"This settlement concludes a four-year government investigation into commercial practices related to Serostim, and we are pleased to put the matter behind us," said Thomas Gunning, vice president and general counsel, Serono U.S., in a statement. "The activities described in the settlement were confined to one unit in our U.S. operations and cover a brief period in our history. Serono takes compliance issues very seriously and has a rigorous compliance program to ensure that its employees meet the highest ethical standards. We now look forward to continuing to focus and devote our energies on our core mission of developing treatments to meet unmet medical needs."
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union